title: [Clinical study on locally advanced rectal cancer patients with pathological complete response after neoadjuvant chemoradiotherapy].
abstract: OBJECTIVE
  To explore the efficacy prediction of the locally advanced rectal cancer patients, especially those with pathological complete response(pCR), receiving neoadjuvant chemoradiotherapy in order to execute precise preoperative neoadjuvant chemoradiotherapy.
  
  
  METHODS
  From January 2000 to January 2011, 125 patients diagnosed as locally advanced rectal cancer receiving preoperative neoadjuvant chemoradiotherapy in our department with complete data were enrolled in this study, including 85 males and 40 females with mean age of 54(15 to 77) years old. All the patients received radiotherapy with 46 Gy(23 times) and administered XELOX regimen (oxaliplatin 100 mg/m(2) plus capecitabine 2 000 mg/m(2)) for 2 courses simultaneously, and underwent radical operation 6 to 8 weeks after chemoradiotherapy. The data of these patients were analyzed retrospectively. Pathological remission was divided into 4 grades. Patients achieving grade 4 were defined as pCR, and those achieving above grade 2 were defined as better response. Logistic regression analysis was used to identify significant predictors of pCR.
  
  
  RESULTS
  Among 125 patients, 16(12.8%) achieved pCR status, and 90(72.0%) had better response to the neoadjuvant chemoradiotherapy. Logistic regression analysis showed that age(OR:1.060, P=0.037) and preoperative positive lymph nodes detected by endorectal ultrasonography (OR:0.059, P=0.006) were independent predictors of pCR after neoadjuvant chemoradiotherapy.
  
  
  CONCLUSIONS
  Preoperative existence of lymph node metastasis around bowel indicates the poor response to neoadjuvant chemoradiotherapy. Age is associated with pCR in patients receiving neoadjuvant chemoradiotherapy.
authors.forename: Gong
authors.initials: G
authors.lastname: Chen
authors.forename: Rongxin
authors.initials: R
authors.lastname: Zhang
authors.forename: Xiaojun
authors.initials: X
authors.lastname: Wu
authors.forename: Zhenhai
authors.initials: Z
authors.lastname: Lu
authors.forename: Peirong
authors.initials: P
authors.lastname: Ding
authors.forename: Zhizhong
authors.initials: Z
authors.lastname: Pan
authors.affiliation: Department of Colorectal Surgery, Cancer Center, Sun Yat-Sen University, State Key Laboratory of Oncology in South China, Guangzhou 510060, China. wands@sysucc.org.cn.
authors.forename: Desen
authors.initials: D
authors.lastname: Wan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069287:Capecitabine / Q000627:therapeutic use; D059248:Chemoradiotherapy; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010071:Oxaloacetates; D012004:Rectal Neoplasms / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D010071:Oxaloacetates; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil